Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Korea Univ. College of Medicine MSTN compound 1
- Development stage
- Preclinical
- Lead developer
- Korea University College of Medicine
- Modality
- Peptides
01
Overview
Korea Univ. College of Medicine MSTN compound 1: sourced facts only. name: "This work establishes compound 1 as a lead prodrug for MSTN antagonism in muscle atrophy." [PMID:42865977]; target: "This work establishes compound 1 as a lead prodrug for MSTN antagonism in muscle atrophy." [PMID:42865977]; developer: "Department of Anatomy, Korea University College of Medicine, 73 Inchon-ro, Seongbuk-gu, Seoul 02841, Republic of Korea." [PMID:42865977]; modality: "We designed all-d tripeptide prodrug mimetics of the MSTN prodomain minimum active 23-mer fragment." [PMID:42865977]; stage: "In vivo, compound 1 increased soleus mass and grip strength in mice." [PMID:42865977]
02
Targets
GDF8 (Myostatin)
Beyond the preview
Go deeper on Korea Univ. College of Medicine MSTN compound 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Korea Univ. College of Medicine MSTN compound 1.